QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Snyder, R. L Articles by Stringham, D. J Search for Related Content PubMed PubMed Citation Articles by Snyder, R. L Articles by Stringham, D. J

Pegfilgrastim-Induced Hyperleukocytosis

Pediatric Oncology/Bone Marrow Transplantation Service, Pharmacy Department, Children's Hospital of Orange County, Orange, CA

Delevan J Stringham, PharmD

Pediatric Oncology/Bone Marrow Transplantation Service, Pharmacy Department, Children's Hospital of Orange County

Reprints: Dr. Snyder, Pharmacy Department, Children's Hospital of Orange County, 455 South Main St., Orange, CA 92868, fax 714/532-8347, rsnyder{at}choc.org

OBJECTIVE: To report a pediatric case of pegfilgrastim-induced hyperleukocytosis.

CASE SUMMARY: A 3-year-old boy with medulloblastoma therapy presented with white blood cell (WBC) count 0.1 x 10³/µL and absolute neutrophil count (ANC) 0.014 x 10³/µL on day 27 following a course of induction chemotherapy. The patient received pegfilgrastim 200 µg/kg the following day. On his return 6 days later for the next planned course of chemotherapy, hyperleukocytosis was determined, with WBC 149 x 10³/µL and ANC 110 x 10³/µL ("neutrophil overshoot"). No sources of the elevated WBC count other than administration of pegfilgrastim (eg, steroids, antiepileptics, infection) were present. Chemotherapy was delayed until the WBC count had fallen to 35.2 x 10³/µL (ANC 28.9 x 10³/µL). No sequelae from this adverse effect occurred.

DISCUSSION: Pegfilgrastim has unique saturable neutrophil receptor-mediated clearance, the ability for self-regulation. Due to this clearance mechanism, hyperleukocytosis associated with pegfilgrastim use is uncommon in adults and has not been previously reported in pediatrics. The pegfilgrastim dose in children is under investigation; however, 100-110 µg/kg has been effective and safe in this population. Use of the Naranjo probability scale suggested that pegfilgrastim was the probable cause of hyperleukocytosis in our patient.

CONCLUSIONS: Pegfilgrastim 200 µg/kg, in excess of the 100 µg/kg dose used in limited pediatric clinical trials, appeared to exceed saturable neutrophil receptor-mediated clearance. The inability of this mechanism to self-regulate neutrophil counts in the normal range led to neutrophil overshoot. Routine pediatric use of the pegylated dosage form of G-CSF should await further published clinical trials to validate a safe and effective dose.

Key Words: filgrastim, hyperleukocytosis, neutropenia, pegfilgrastim, pediatrics

Published Online, July 31, 2007. www.theannals.com, DOI 10.1345/aph.1K093

This article has been cited by other articles:

				N. Andre, E. Milano, A. Rome, and J. C. Gentet Safety of Pegfilgrastim in Children Ann. Pharmacother., February 1, 2008; 42(2): 290 - 290. [Full Text] [PDF]